Racial differences in the expression of inhibitors of apoptosis from prostate cancer patients
African-American men with prostate cancer typically develop more aggressive tumors than men from other racial/ethnic groups, resulting in a disproportionately high mortality from this malignancy. This study evaluated differences in the expression of inhibitors of apoptosis proteins (IAPs), a known f...
Gespeichert in:
| Veröffentlicht in: | PloS one 2017-10, Vol.12 (10), p.e0183122 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | e0183122 |
| container_title | PloS one |
| container_volume | 12 |
| creator | Khan, Salma Simpson, Jennifer Lynch, James C Turay, David Mirshahidi, Saied Gonda, Amber Sanchez, Tino W Casiano, Carlos A Wall, Nathan R |
| description | African-American men with prostate cancer typically develop more aggressive tumors than men from other racial/ethnic groups, resulting in a disproportionately high mortality from this malignancy. This study evaluated differences in the expression of inhibitors of apoptosis proteins (IAPs), a known family of oncoproteins, in blood-derived exosomal vesicles (EV) between African-American and European-American men with prostate cancer. The ExoQuick.sup.[TM] method was used to isolate EV from both plasma and sera of African-American (n = 41) and European-American (n = 31) men with prostate cancer, as well as from controls with no cancer diagnosis (n = 10). EV preparations were quantified by acetylcholinesterase activity assays, and assessed for their IAP content by Western blotting and densitometric analysis. Circulating levels of the IAP Survivin were evaluated by ELISA. We detected a significant increase in the levels of circulating Survivin in prostate cancer patients compared to controls (P |
| doi_str_mv | 10.1371/journal.pone.0183122 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A508208880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A508208880</galeid><sourcerecordid>A508208880</sourcerecordid><originalsourceid>FETCH-LOGICAL-g670-a55c03052425781aa6c3cee45a92e489954488131674ad1193767ee3fa5ab5693</originalsourceid><addsrcrecordid>eNptUE1LAzEUDKJgrf4DDwHPu-Zjk80eS_ELCoL0KuU1fWlTtsmSRPDnG9GDB3mHeTPMG3hDyC1nLZc9vz_GjxRgbKcYsGXcSC7EGZnxQYpGCybP_-yX5CrnI2NKGq1n5P0NrIeR7rxzmDBYzNQHWg5I8XNKmLOPgUZXxYPf-hJT_mYwxanE7DN1KZ7olGIuUJBaqAmJTlA8hpKvyYWDMePNL87J-vFhvXxuVq9PL8vFqtnrnjWglGWSKdEJ1RsOoK20iJ2CQWBnhkF1nTFcct13sOP1lV73iNKBgq3Sg5yTu5_YPYy48cHFksCefLabhWJGMGMMq672H1edHZ68rdU5X_U_B185T2fD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Racial differences in the expression of inhibitors of apoptosis from prostate cancer patients</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Khan, Salma ; Simpson, Jennifer ; Lynch, James C ; Turay, David ; Mirshahidi, Saied ; Gonda, Amber ; Sanchez, Tino W ; Casiano, Carlos A ; Wall, Nathan R</creator><creatorcontrib>Khan, Salma ; Simpson, Jennifer ; Lynch, James C ; Turay, David ; Mirshahidi, Saied ; Gonda, Amber ; Sanchez, Tino W ; Casiano, Carlos A ; Wall, Nathan R</creatorcontrib><description><![CDATA[African-American men with prostate cancer typically develop more aggressive tumors than men from other racial/ethnic groups, resulting in a disproportionately high mortality from this malignancy. This study evaluated differences in the expression of inhibitors of apoptosis proteins (IAPs), a known family of oncoproteins, in blood-derived exosomal vesicles (EV) between African-American and European-American men with prostate cancer. The ExoQuick.sup.[TM] method was used to isolate EV from both plasma and sera of African-American (n = 41) and European-American (n = 31) men with prostate cancer, as well as from controls with no cancer diagnosis (n = 10). EV preparations were quantified by acetylcholinesterase activity assays, and assessed for their IAP content by Western blotting and densitometric analysis. Circulating levels of the IAP Survivin were evaluated by ELISA. We detected a significant increase in the levels of circulating Survivin in prostate cancer patients compared to controls (P<0.01), with the highest levels in African-American patients (P<0.01). African-American patients with prostate cancer also contained significantly higher amounts of EVs in their plasma (P<0.01) and sera (P<0.05) than European-American patients. In addition, EVs from African-American patients with prostate cancer contained significantly higher amounts of the IAPs Survivin (P<0.05), XIAP (P<0.001), and cIAP-2 (P<0.01) than EVs from European-American patients. There was no significant correlation between expression of IAPs and clinicopathological parameters in the two patient groups. Increased expression of IAPs in EVs from African-American patients with prostate cancer may influence tumor aggressiveness and contribute to the mortality disparity observed in this patient population. EVs could serve as reservoirs of novel biomarkers and therapeutic targets that may have clinical utility in reducing prostate cancer health disparities.]]></description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0183122</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Cancer patients ; Gene expression ; Genetic aspects ; Health aspects ; Inhibitor of apoptosis proteins ; Prostate cancer ; Race discrimination</subject><ispartof>PloS one, 2017-10, Vol.12 (10), p.e0183122</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Khan, Salma</creatorcontrib><creatorcontrib>Simpson, Jennifer</creatorcontrib><creatorcontrib>Lynch, James C</creatorcontrib><creatorcontrib>Turay, David</creatorcontrib><creatorcontrib>Mirshahidi, Saied</creatorcontrib><creatorcontrib>Gonda, Amber</creatorcontrib><creatorcontrib>Sanchez, Tino W</creatorcontrib><creatorcontrib>Casiano, Carlos A</creatorcontrib><creatorcontrib>Wall, Nathan R</creatorcontrib><title>Racial differences in the expression of inhibitors of apoptosis from prostate cancer patients</title><title>PloS one</title><description><![CDATA[African-American men with prostate cancer typically develop more aggressive tumors than men from other racial/ethnic groups, resulting in a disproportionately high mortality from this malignancy. This study evaluated differences in the expression of inhibitors of apoptosis proteins (IAPs), a known family of oncoproteins, in blood-derived exosomal vesicles (EV) between African-American and European-American men with prostate cancer. The ExoQuick.sup.[TM] method was used to isolate EV from both plasma and sera of African-American (n = 41) and European-American (n = 31) men with prostate cancer, as well as from controls with no cancer diagnosis (n = 10). EV preparations were quantified by acetylcholinesterase activity assays, and assessed for their IAP content by Western blotting and densitometric analysis. Circulating levels of the IAP Survivin were evaluated by ELISA. We detected a significant increase in the levels of circulating Survivin in prostate cancer patients compared to controls (P<0.01), with the highest levels in African-American patients (P<0.01). African-American patients with prostate cancer also contained significantly higher amounts of EVs in their plasma (P<0.01) and sera (P<0.05) than European-American patients. In addition, EVs from African-American patients with prostate cancer contained significantly higher amounts of the IAPs Survivin (P<0.05), XIAP (P<0.001), and cIAP-2 (P<0.01) than EVs from European-American patients. There was no significant correlation between expression of IAPs and clinicopathological parameters in the two patient groups. Increased expression of IAPs in EVs from African-American patients with prostate cancer may influence tumor aggressiveness and contribute to the mortality disparity observed in this patient population. EVs could serve as reservoirs of novel biomarkers and therapeutic targets that may have clinical utility in reducing prostate cancer health disparities.]]></description><subject>Cancer patients</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Inhibitor of apoptosis proteins</subject><subject>Prostate cancer</subject><subject>Race discrimination</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptUE1LAzEUDKJgrf4DDwHPu-Zjk80eS_ELCoL0KuU1fWlTtsmSRPDnG9GDB3mHeTPMG3hDyC1nLZc9vz_GjxRgbKcYsGXcSC7EGZnxQYpGCybP_-yX5CrnI2NKGq1n5P0NrIeR7rxzmDBYzNQHWg5I8XNKmLOPgUZXxYPf-hJT_mYwxanE7DN1KZ7olGIuUJBaqAmJTlA8hpKvyYWDMePNL87J-vFhvXxuVq9PL8vFqtnrnjWglGWSKdEJ1RsOoK20iJ2CQWBnhkF1nTFcct13sOP1lV73iNKBgq3Sg5yTu5_YPYy48cHFksCefLabhWJGMGMMq672H1edHZ68rdU5X_U_B185T2fD</recordid><startdate>20171005</startdate><enddate>20171005</enddate><creator>Khan, Salma</creator><creator>Simpson, Jennifer</creator><creator>Lynch, James C</creator><creator>Turay, David</creator><creator>Mirshahidi, Saied</creator><creator>Gonda, Amber</creator><creator>Sanchez, Tino W</creator><creator>Casiano, Carlos A</creator><creator>Wall, Nathan R</creator><general>Public Library of Science</general><scope/></search><sort><creationdate>20171005</creationdate><title>Racial differences in the expression of inhibitors of apoptosis from prostate cancer patients</title><author>Khan, Salma ; Simpson, Jennifer ; Lynch, James C ; Turay, David ; Mirshahidi, Saied ; Gonda, Amber ; Sanchez, Tino W ; Casiano, Carlos A ; Wall, Nathan R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g670-a55c03052425781aa6c3cee45a92e489954488131674ad1193767ee3fa5ab5693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Cancer patients</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Inhibitor of apoptosis proteins</topic><topic>Prostate cancer</topic><topic>Race discrimination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Salma</creatorcontrib><creatorcontrib>Simpson, Jennifer</creatorcontrib><creatorcontrib>Lynch, James C</creatorcontrib><creatorcontrib>Turay, David</creatorcontrib><creatorcontrib>Mirshahidi, Saied</creatorcontrib><creatorcontrib>Gonda, Amber</creatorcontrib><creatorcontrib>Sanchez, Tino W</creatorcontrib><creatorcontrib>Casiano, Carlos A</creatorcontrib><creatorcontrib>Wall, Nathan R</creatorcontrib><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Salma</au><au>Simpson, Jennifer</au><au>Lynch, James C</au><au>Turay, David</au><au>Mirshahidi, Saied</au><au>Gonda, Amber</au><au>Sanchez, Tino W</au><au>Casiano, Carlos A</au><au>Wall, Nathan R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Racial differences in the expression of inhibitors of apoptosis from prostate cancer patients</atitle><jtitle>PloS one</jtitle><date>2017-10-05</date><risdate>2017</risdate><volume>12</volume><issue>10</issue><spage>e0183122</spage><pages>e0183122-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract><![CDATA[African-American men with prostate cancer typically develop more aggressive tumors than men from other racial/ethnic groups, resulting in a disproportionately high mortality from this malignancy. This study evaluated differences in the expression of inhibitors of apoptosis proteins (IAPs), a known family of oncoproteins, in blood-derived exosomal vesicles (EV) between African-American and European-American men with prostate cancer. The ExoQuick.sup.[TM] method was used to isolate EV from both plasma and sera of African-American (n = 41) and European-American (n = 31) men with prostate cancer, as well as from controls with no cancer diagnosis (n = 10). EV preparations were quantified by acetylcholinesterase activity assays, and assessed for their IAP content by Western blotting and densitometric analysis. Circulating levels of the IAP Survivin were evaluated by ELISA. We detected a significant increase in the levels of circulating Survivin in prostate cancer patients compared to controls (P<0.01), with the highest levels in African-American patients (P<0.01). African-American patients with prostate cancer also contained significantly higher amounts of EVs in their plasma (P<0.01) and sera (P<0.05) than European-American patients. In addition, EVs from African-American patients with prostate cancer contained significantly higher amounts of the IAPs Survivin (P<0.05), XIAP (P<0.001), and cIAP-2 (P<0.01) than EVs from European-American patients. There was no significant correlation between expression of IAPs and clinicopathological parameters in the two patient groups. Increased expression of IAPs in EVs from African-American patients with prostate cancer may influence tumor aggressiveness and contribute to the mortality disparity observed in this patient population. EVs could serve as reservoirs of novel biomarkers and therapeutic targets that may have clinical utility in reducing prostate cancer health disparities.]]></abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0183122</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2017-10, Vol.12 (10), p.e0183122 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A508208880 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Cancer patients Gene expression Genetic aspects Health aspects Inhibitor of apoptosis proteins Prostate cancer Race discrimination |
| title | Racial differences in the expression of inhibitors of apoptosis from prostate cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A21%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Racial%20differences%20in%20the%20expression%20of%20inhibitors%20of%20apoptosis%20from%20prostate%20cancer%20patients&rft.jtitle=PloS%20one&rft.au=Khan,%20Salma&rft.date=2017-10-05&rft.volume=12&rft.issue=10&rft.spage=e0183122&rft.pages=e0183122-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0183122&rft_dat=%3Cgale%3EA508208880%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A508208880&rfr_iscdi=true |